Stevanato Group S.p.A.
STVN Healthcare Medical Instruments & Supplies
Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS fell 25.0%, free cash flow fell 167.0% and total debt rose 9.27%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for five, operating cash flow growth for three.
Follow STVN
Stevanato Group S.p.A. (STVN) EV/Sales
As of 16 October 2026, Stevanato Group S.p.A. (STVN) trades at a EV/Sales of 3.9×. Over the past ten years it has ranged from 2.9× (April 2026) to 8.8× (August 2023); the current reading is higher than 12% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.4× | (16.75%) |
| FY2024 | 5.2× | (16.58%) |
| FY2023 | 6.3× | 42.26% |
| FY2022 | 4.4× | (18.94%) |
| FY2021 | 5.5× | (8.35%) |
| FY2020 | 6.0× | 0.00% |
| FY2019 | 6.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.7× | 26.08% |
| Mar 2026 | 3.0× | (31.94%) |
| Dec 2025 | 4.4× | (23.66%) |
| Sep 2025 | 5.7× | 1.67% |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVST Envista Holdings Corporation compare | 1.4× |
| BLCO Bausch + Lomb Corporation compare | 2.0× |
| ATR AptarGroup, Inc. compare | 2.3× |
| ICUI ICU Medical, Inc. compare | 2.3× |
| WRBY Warby Parker Inc. compare | 2.9× |
| MMSI Merit Medical Systems, Inc. compare | 3.6× |
| TFX Teleflex Incorporated compare | 3.6× |
| STVN Stevanato Group S.p.A. | 3.9× |
| PLSE Pulse Biosciences, Inc compare | 2,555× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)